The Bladder Cancer Company

About Us

Our Values

Our History

Bladder cancer challenge

Board of directors

Executive Leadership

Leadership

Our Company

Precision Diagnostics

Our products

Research support

Innovation & Products

News

The Importance of Health Economics​

Bladder Cancer and AI

Addressing Inequality

Our Perspective

Patient Registries And Real-World Evidence

Bladder cancer community support

Corporate social responsibility

ESG Report

Our Impact

Why Partner with Photocure

Our Partners

Partners

Photocure culture

Working at Photocure

Careers

Contact

Events & Presentations

Financials

Shareholder information

FAQs

Investors hub

Investors

Press & Media

Privacy Policy

Terms of use

cevira

large_shareholders.png

medium_shareholders.png

small_shareholders.png

thumbnail_shareholders.png

Shareholders

ESG report

New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer

Medical Information

Photocure ASA: Invitation to presentation of first quarter 2026 financial results

Photocure ASA: Annual Report 2025

Financial Investment & Stock

Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals

Asieris publishes Annual Report and shares Market approval of Richard Wolf System blue equipment in China

Product Announcements

Partnership News & Expansion

Photocure ASA: Update on Regulatory Classification for OAY Equipment

Blue Light Cystoscopy demonstrates cost neutrality through reduced recurrence in real-world BRAVO study 

Real World Evidence

Update on KARL STORZ’s Citizen Petition

Asieris: Cevira Endorsed with Level 1A Evidence in Expert Consensus

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Medical congresses & events

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe

Photocure ASA: Results for the fourth quarter of 2025

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

New publication: examining 12-months recurrence-free survival following photo coagulation of bladder tumor versus TUR-BT 

<p>We use cookies to provide the best possible experience for you. By closing this message you agree to our use of cookies. You can learn more about cookies on our <a href="https://photocure.com/privacy-policy" target="_blank" rel="noopener noreferrer">privacy page</a>.</p>

agree

Shareholders

Investor news